Senior Correspondent, London
Ben's Feed
Jul 11, 2014
Jul 10, 2014
Jul 9, 2014
Jul 9, 2014

AbbVie forced to retract comments in Shire takeover fight

LONDON, July 9 (Reuters) – U.S. drugmaker AbbVie
has been forced to retract comments by its chief executive about
shareholder support for its bid for Shire after being
caught out by British takeover rules.

Chief Executive Richard Gonzalez told Reuters in an
interview on Tuesday he believed major Shire investors were
“generally supportive of this transaction” – a comment he
repeated in conversations with other media.

Jul 8, 2014

AbbVie hikes bid for drugmaker Shire to $51 billion

LONDON (Reuters) – U.S. drugmaker AbbVie (ABBV.N: Quote, Profile, Research, Stock Buzz) raised its offer for Shire (SHP.L: Quote, Profile, Research, Stock Buzz) to 30.1 billion pounds ($51.3 billion) on Tuesday, hoping to win over its reluctant target after three earlier offers were rejected.

The latest 51.15 pounds a share cash-and-stock offer is 11 percent higher than AbbVie’s previous proposal of 46.26 pounds, which the London-listed hyperactivity and rare diseases specialist had said fundamentally undervalued the company.

Jul 8, 2014
Jul 6, 2014
Jul 6, 2014

Insight – How to fix a broken market in antibiotics

LONDON (Reuters) – The drugs don’t work – and neither does the market, when it comes to antibiotics.

When sophisticated bugs that medicines used to kill within days start to fight back and win, all of healthcare, and the people it keeps alive, is in trouble.

Jul 6, 2014

How to fix a broken market in antibiotics

LONDON, July 6 (Reuters) – The drugs don’t work – and
neither does the market, when it comes to antibiotics.

When sophisticated bugs that medicines used to kill within
days start to fight back and win, all of healthcare, and the
people it keeps alive, is in trouble.

Jul 3, 2014

AbbVie presses case for Shire deal in discreet roadshow

LONDON, July 3 (Reuters) – AbbVie Chief Executive
Richard Gonzalez has pressed the case for his $46 billion
pursuit of drugmaker Shire in discreet meetings with
shareholders in London this week and is now weighing his next
move, according to people familiar with the matter.

Shire shareholders who met with Gonzalez said he had
reiterated the case for a deal, arguing that AbbVie would create
more value from Shire’s assets than the hyperactivity and rare
diseases specialist could do on its own.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben